EstroTep

Radiopharmaceutical Authorized in France
molecule-estrotep

Breast cancer is the first cancer among women, both in the US and Europe and current treatments for metastatic breast cancer (MBC) combine biopsy, chemio-, radio- and hormono-therapies. But biopsies are not always possible, on all tumors, which is a key concern for MBC. Thus, a comprehensive quantification of receptors as well as the characterization of all hormono-dependant cancer expressing receptors are not possible with biopsies. EstroTep is a PET imaging radiopharmaceutical authorized in France capable of characterizing metastatic lesions, known or suspected, as expressing estrogen receptors in adult breast cancer, initially expressing the estrogen receptor, as per French Marketing Authorization. EstroTep targets REα Receptors. 

As a complement to biopsy, EstroTep imaging allows a comprehensive quantification of receptors as well as the caracterization of all hormono-dependant receptors.EstroTep allows a whole body and non-invasive metabolic imaging, to visualize disseminated ER (+) tumors, especially in non-accessible areas. 

Population

Female/male with REα hormono-dependant metastatic breast cancer (MBC)

Epidemiology

  • US breast cancer incidence : 250k new patients per year
  • US breast cancer prevalence (5 years) : 1,2m patients, of which 80% hormo-dependant, of which 15% metastatic (MBC)
  • France breast cancer incidence : 52k new patients per year
  • France breast cancer prevalence (5 years) : 250k patients, of which 80% hormo-dependant, of which 15% metastatic (MBC)

Next Generation Cdx Pipeline for Molecular
Imaging

Find out more about what’s coming in CDx imaging